Leerink Partners maintained an Outperform rating on Mirna Therapeutics (NASDAQ: MIRN), and cut the price target to $10.00 (from $14.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Mirna Therapeutics Provides Operational Update and Reports Financial Results for Fourth Quarter and Full Year Ended December 31, 2015March 29, 2016 4:03 PM Trading Radar for 3/29: Conn's (CONN), Lennar (LEN), McCormick (MKC), Restoration Hardware (RH) ReportMarch 28, 2016 3:48 PM